Dr Reddy’s launches anti-coagulant drug in US market

New Delhi: Drug major Dr Reddy’s Laboratories Monday announced the launch of anti-coagulant drug Aspirin and extended-release dipyridamole capsules in the US market. The product is a therapeutic equivalent to generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules, the company said in a BSE filing.

Quoting IMS Health data, Dr Reddy’s Laboratories said the Aggrenox brand and generic had US sales of approximately USD 182 million for the most recent 12 months ending in October 2018.

Dr Reddy’s Aspirin and extended-release Dipyridamole capsules is available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a trademark of Boehringer lngelheim.

Stock of Dr Reddy’s Laboratories was trading 0.48 per cent lower at Rs 2,591.45 apiece on BSE.

  • Related Posts

    WHO launches new primary health care course to strengthen health systems globally

    Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert